Adjuvant Capital

Adjuvant Capital

A New York-based venture capital firm that focuses on life science companies

Adjuvant Capital is a venture capital firm that prefers to invest in businesses in the life science sector. Founded in 2012 by Charlie Petty, Glenn Rockman, and Kabeer Aziz in New York, New York. The firm invests in Early Stage Venture. The notable investment portfolio of the Adjuvant Capital includes AN2 Therapeutics, Themis, InDevR, and X-Vax.

As of December 2019, Sony Innovation Fund has made 4 investments and actively looking for new investment opportunities. Adjuvant Capital typically invests around $10-$25 million.

Timeline

2012

Founded

Funded Companies

Company
Description
Industry
Website
Location
Codagenix

A biotechnology company developing live attenuated vaccines. It was founded in 2012 and is located in New York.

Biotechnology
Farmingdale, New York
Themis Bioscience

A biotechnology company developing immune-modulation therapies for infectious diseases and cancer leveraging its technology platform and understanding of immune system mechanisms. It was founded in 2009 and is located in Vienna, Austria.

Biotechnology
Vienna
InDevR

Boulder-based biotech company specializing in microarray technology and applications

Biotechnology
Boulder, Colorado
3 Results
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Charlie Petty

Principal

Christian Mandl

SENIOR ADVISOR / BOSTON

Curt LaBelle

VENTURE PARTNER / NEW YORK

Evelyn Yanatos

FINANCE DIRECTOR / NEW YORK

Gerard Cunningham

OPERATING PARTNER

Glenn Rockman

FOUNDER / MANAGING PARTNER / NEW YORK

Jenny Yip

MANAGING PARTNER / SAN FRANCISCO

Jim Robinson

SENIOR ADVISOR

Kabeer Aziz

PRINCIPAL / NEW YORK

Kim Kamdar

PARTNER / SAN DIEGO

Lilly deSouza Burr

ASSOCIATE / NEW YORK

Mark Sullivan

VENTURE PARTNER

Michael Chang

PRINCIPAL / NEW YORK

Peter Patriarca

SENIOR ADVISOR / DC

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

AN2 Therapeutics

InDevR

Themis Bioscience

X-Vax Technology

News

Title
Author
Date
Publisher
Description
Jake Bright
April 14, 2020
TechCrunch
Greater availability of African genomic data could lead to medical breakthroughs for the continent's 1.2 billion people. That's the driving proposition of 54gene -- a U.S. and Nigeria based startup -- that collects African genetic code for use in health research and drug development. The company has closed a $15 million Series A round, in [...]

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.